c-MET在非小细胞肺癌中的研究现状
Current Research Status of c-MET in Non-Small Cell Lung Cancer
DOI: 10.12677/acm.2024.1441108, PDF,   
作者: 马雨琪, 黄子静, 马军伟, 冯 蓓*：延安大学附属医院肿瘤科，陕西 延安
关键词: 非小细胞肺癌；MET；耐药；靶向治疗；Non Small Cell Lung Cancer； MET； Drug Resistance； Targeted Therapy
摘要: 非小细胞肺癌(NSCLC)是一种异质性疾病，可由许多基因突变驱动发生。间质–上皮细胞转化因子(MET)是继表皮生长因子受体(EGFR)、间变性淋巴瘤激酶(ALK)等之后的又一热门研究靶点。MET异常已被证实在多种致癌中，促进肿瘤侵袭、血管生成和转移。c-MET不仅是独立的肺癌驱动因子，也是介导其他驱动基因靶向治疗耐药的副驱动因子。目前，针对c-Met通路的治疗策略主要包括单克隆抗体和靶向MET基因的小分子TKIs。作者对MET改变的NSCLC的研究现状及治疗进展进行综述。
Abstract: Non small cell lung cancer (NSCLC) is a heterogeneous disease that can be driven by many genetic mutations. Mesenchymal epithelial transition factor (MET) is another popular research target, following epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and others. MET abnormalities have been proven to promote tumor invasion, angiogenesis, and metastasis in various carcinogens. C-MET is not only an independent driving factor for lung cancer, but also a side driving factor that mediates the targeted treatment of drug resistance by other driving genes. At present, treatment strategies for the c-Met pathway mainly include monoclonal antibodies and small molecule TKIs targeting the MET gene. The author provides a review of the current research status and treatment progress of MET induced NSCLC.
文章引用：马雨琪, 黄子静, 马军伟, 冯蓓. c-MET在非小细胞肺癌中的研究现状[J]. 临床医学进展, 2024, 14(4): 932-940. https://doi.org/10.12677/acm.2024.1441108

参考文献

[1] Han, B., Zheng, R., Zeng, H., et al. (2024) Cancer Incidence and Mortality in China, 2022. Journal of the National Cancer Center, 4, 47-53. [Google Scholar] [CrossRef] [PubMed]
[2] Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung Cancer. The New England Journal of Medicine, 359, 1367-1380. [Google Scholar] [CrossRef] 
[3] Wen, S., Dai, L., Wang, L., et al. (2019) Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. The Oncologist, 24, e1070-e1081. [Google Scholar] [CrossRef] [PubMed]
[4] Furge, K.A., Zhang, Y.W. and Vande Woude, G.F. (2000) Met Receptor Tyrosine Kinase: Enhanced Signaling through Adapter Proteins. Oncogene, 19, 5582-5589. [Google Scholar] [CrossRef] [PubMed]
[5] Vuong, H.G., Ho, A.T.N., Altibi, A.M.A., et al. (2018) Clinicopathological Implications of MET Exon 14 Mutations in Non-Small Cell Lung Cancer—A Systematic Review and Meta-Analysis. Lung Cancer, 123, 76-82. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, N., Zhu, Y., Wu, Y., et al. (2022) MET Overexpression in EGFR L858R Mutant Treatment-Naïve Advanced Lung Adenocarcinoma Correlated with Poor Prognosis: A Real-World Retrospective Study. Journal of Cancer Research and Clinical Oncology, 149, 3219-3228. [Google Scholar] [CrossRef] [PubMed]
[7] Cortot, A.B., Kherrouche, Z., Descarpentries, C., et al. (2017) Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. Journal of the National Cancer Institute, 109, Article djw262. [Google Scholar] [CrossRef] [PubMed]
[8] Liu, Y. (1998) The Human Hepatocyte Growth Factor Receptor Gene: Complete Structural Organization and Promoter Characterization. Gene, 215, 159-169. [Google Scholar] [CrossRef] 
[9] Organ, S.L. and Tsao, M.S. (2011) An Overview of the c-MET Signaling Pathway. Therapeutic Advances in Medical Oncology, 3, S7-S19. [Google Scholar] [CrossRef] [PubMed]
[10] Sonnenberg, E., Meyer, D., Weidner, K.M., et al. (1993) Scatter Factor/Hepatocyte Growth Factor and Its Receptor, the c-Met Tyrosine Kinase, Can Mediate a Signal Exchange between Mesenchyme and Epithelia during Mouse Development. Journal of Cell Biology, 123, 223-235. [Google Scholar] [CrossRef] [PubMed]
[11] Kong-Beltran, M., Stamos, J. and Wickramasinghe, D. (2004) The Sema Domain of Met Is Necessary for Receptor Dimerization and Activation. Cancer Cell, 6, 75-84. [Google Scholar] [CrossRef] [PubMed]
[12] Cooper, C.S., Park, M., Blair, D.G., et al. (1984) Molecular Cloning of a New Transforming Gene from a Chemically Transformed Human Cell Line. Nature, 311, 29-33. [Google Scholar] [CrossRef] [PubMed]
[13] Guo, B., Cen, H., Tan, X., et al. (2014) Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures. PLOS ONE, 9, e99399. [Google Scholar] [CrossRef] [PubMed]
[14] Leardini, D., Messelodi, D., Muratore, E., et al. (2022) Role of CBL Mutations in Cancer and Non-Malignant Phenotype. Cancers, 14, Article 839. [Google Scholar] [CrossRef] [PubMed]
[15] Kong-Beltran, M., Seshagiri, S., Zha, J., et al. (2006) Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer. Cancer Research, 66, 283-289. [Google Scholar] [CrossRef] 
[16] Frampton, G.M., Ali, S.M., Rosenzweig, M., et al. (2015) Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery, 5, 850-859. [Google Scholar] [CrossRef] 
[17] Mazieres, J., Vioix, H., Pfeiffer, B.M., et al. (2023) MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clinical Lung Cancer, 24, 483-497. [Google Scholar] [CrossRef] [PubMed]
[18] Recondo, G., Guo, R., Cravero, P., et al. (2020) Clinical Characteristics, Genomic Features, and Recurrence Risk of Early-Stage MET Exon 14 Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 38, 9042. [Google Scholar] [CrossRef] 
[19] Lamberti, G., Li, Y., Spurr, L., et al. (2019) P2.04-32 Comparison of Clinicopathological and Genomic Characteristics between NSCLCs with a PD-L1 Tumor Proportion Score of ≥90% vs. <1%. Journal of Thoracic Oncology, 14, S720-S721. [Google Scholar] [CrossRef] 
[20] Hellman, A., Zlotorynski, E., Scherer, S.W., et al. (2002) A Role for Common Fragile Site Induction in Amplification of Human Oncogenes. Cancer Cell, 1, 89-97. [Google Scholar] [CrossRef] 
[21] Drilon, A., Cappuzzo, F., Ou, S.I., et al. (2017) Targeting MET in Lung Cancer: Will Expectations Finally Be MET? Journal of Thoracic Oncology, 12, 15-26. [Google Scholar] [CrossRef] [PubMed]
[22] Schubart, C., Stöhr, R., Tögel, L., et al. (2021) MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting. Cancers, 13, Article 5023. [Google Scholar] [CrossRef] [PubMed]
[23] Peng, L.-X., Jie, G.-L., Li, A.-N., et al. (2021) MET Amplification Identified by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors. Experimental Hematology & Oncology, 10, Article No. 52. [Google Scholar] [CrossRef] [PubMed]
[24] Cappuzzo, F., Jänne, P.A., Skokan, M., et al. (2009) MET Increased Gene Copy Number and Primary Resistance to Gefitinib Therapy in Non-Small-Cell Lung Cancer Patients. Annals of Oncology, 20, 298-304. [Google Scholar] [CrossRef] [PubMed]
[25] Camidge, D.R., Otterson, G.A., Clark, J.W., et al. (2021) Crizotinib in Patients with MET-Amplified NSCLC. Journal of Thoracic Oncology, 16, 1017-1029. [Google Scholar] [CrossRef] [PubMed]
[26] Wolf, J., Seto, T., Han, J.Y., et al. (2020) Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 383, 944-957. [Google Scholar] [CrossRef] 
[27] Engelman, J.A., Zejnullahu, K., Mitsudomi, T., et al. (2007) MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 316, 1039-1043. [Google Scholar] [CrossRef] [PubMed]
[28] Chmielecki, J., Mok, T., Wu, Y.L., et al. (2023) Analysis of Acquired Resistance Mechanisms to Osimertinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer from the AURA3 Trial. Nature Communications, 14, Article No. 1071. [Google Scholar] [CrossRef] [PubMed]
[29] Coleman, N., Hong, L., Zhang, J., et al. (2021) Beyond Epidermal Growth Factor Receptor: MET Amplification as a General Resistance Driver to Targeted Therapy in Oncogene-Driven Non-Small-Cell Lung Cancer. ESMO Open, 6, Article 100319. [Google Scholar] [CrossRef] [PubMed]
[30] Dagogo-Jack, I., Yoda, S., Lennerz, J.K., et al. (2020) MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical Cancer Research, 26, 2535-2545. [Google Scholar] [CrossRef] 
[31] Guo, R., Berry, L.D., Aisner, D.L., et al. (2019) MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. Journal of Thoracic Oncology, 14, 1666-1671. [Google Scholar] [CrossRef] [PubMed]
[32] Liam, C.K., Ahmad, A.R., Hsia, T.C., et al. (2023) Randomized Trial of Tepotinib plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research, 29, 1879-1886. [Google Scholar] [CrossRef] 
[33] Paik, P.K., Drilon, A., Fan, P.D., et al. (2015) Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discovery, 5, 842-849. [Google Scholar] [CrossRef] 
[34] Kim, T.M., Guarneri, V., Jye, V.P., et al. (2023) OA21.05 Tepotinib Osimertinib in EGFR-Mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis. Journal of Thoracic Oncology, 18, S94. [Google Scholar] [CrossRef] 
[35] Lu, S., Fang, J., Li, X., et al. (2021) Once-Daily Savolitinib in Chinese Patients with Pulmonary Sarcomatoid Carcinomas and Other Non-Small-Cell Lung Cancers Harbouring MET Exon 14 Skipping Alterations: A Multicentre, Single-Arm, Open-Label, Phase 2 Study. The Lancet Respiratory Medicine, 9, 1154-1164. [Google Scholar] [CrossRef] 
[36] Lu, S., Yu, Y., Guo, Q., et al. (2023) OA21.03 a Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation. Journal of Thoracic Oncology, 18, S92-S93. [Google Scholar] [CrossRef] 
[37] Sequist, L.V., Han, J.-Y., Ahn, M.-J., et al. (2020) Osimertinib plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small-Cell Lung Cancer after Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results from a Multicentre, Open-Label, Phase 1b Study. The Lancet Oncology, 21, 373-386. [Google Scholar] [CrossRef] 
[38] Leighl, N., Cho, B.C., Hiret, S., et al. (2023) OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. Journal of Thoracic Oncology, 18, S93-S94. [Google Scholar] [CrossRef] 
[39] Cho, B.C., Felip, E., Spira, A.I., et al. (2023) LBA14 Amivantamab plus Lazertinib vs Osimertinib as First-Line Treatment in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results from MARIPOSA, a Phase III, Global, Randomized, Controlled Trial. Annals of Oncology, 34, S1306. [Google Scholar] [CrossRef] 
[40] Lee, S.H., Cho, B.C., Spira, A.I., et al. (2023) MA13.06 Amivantamab, Lazertinib plus Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC: Updated Results from CHRYSALIS-2. Journal of Thoracic Oncology, 18, S146-S147. [Google Scholar] [CrossRef] 
[41] Passaro, A., Cho, B.C., Wang, Y., et al. (2023) LBA15 Amivantamab plus Chemotherapy (with or without Lazertinib) vs Chemotherapy in EGFR-Mutated Advanced NSCLC after Progression on Osimertinib: MARIPOSA-2, a Phase III, Global, Randomized, Controlled Trial. Annals of Oncology, 34, S1307. [Google Scholar] [CrossRef] 

为你推荐